Literature DB >> 23087846

Prostaglandin E2: a putative potency indicator of the immunosuppressive activity of human mesenchymal stem cells.

Luis A Solchaga1, Elizabeth A Zale.   

Abstract

Mesenchymal stem cells (MSCs) are non-hematopoietic, pluripotent cells that give rise to stromal cells in the marrow. MSCs have been shown to be immunosuppressive and have become an attractive therapeutic option for the modulation of undesired immune responses. Currently, ex vivo expanded human (h)MSCs are being utilized in clinical trials both in the USA and in Europe to treat a variety of immune disorders. hMSCs need to be harvested, isolated and expanded in culture. This necessary expansion may also result in decrease or loss of the immunomodulatory potential of hMSCs. Ideally, the intrinsic immunomodulatory activity (potency) of an hMSC preparation should be assessed prior to its administration. The goal of the experiments described here was to develop a simple potency assay for the immunomodulatory properties of hMSCs. The immunosuppressive activity of hMSCs conditioned media was tested in enzyme-linked immunosorbent spot assays (ELISpot) and the immunosuppressive activity of the conditioned media was correlated with the concentration of several cytokines present in these conditioned media. The concentration of prostaglandin E(2) in the media correlated with their immunosuppressive activity. The concentration of the other cytokines measured did not correlate with the immunosuppressive activity of the media. The dose-response effect could be replicated by adding PGE(2) to ELISpot assays. Furthermore, the immunosuppressive activity of the conditioned media was inhibitable by a neutralizing anti-PGE(2) antibody. These data suggest that measurement of PGE(2) in media conditioned by hMSCs exposed to inflammatory stimuli could be used as a surrogate measure of their immunosuppressive capacity. These findings need to be confirmed in vitro using different assays of immune function and validated in vivo to determine the level of correlation of these data with efficacy in pre-clinical models of immune disorders.

Entities:  

Year:  2012        PMID: 23087846      PMCID: PMC3475534     

Source DB:  PubMed          Journal:  Am J Stem Cells        ISSN: 2160-4150


  23 in total

1.  Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells.

Authors:  Ida Rasmusson; Olle Ringdén; Berit Sundberg; Katarina Le Blanc
Journal:  Transplantation       Date:  2003-10-27       Impact factor: 4.939

2.  Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells.

Authors:  Margaret E Groh; Basabi Maitra; Emese Szekely; Omer N Koç
Journal:  Exp Hematol       Date:  2005-08       Impact factor: 3.084

3.  The immunosuppressive properties of mesenchymal stem cells.

Authors:  Georg Siegel; Richard Schäfer; Francesco Dazzi
Journal:  Transplantation       Date:  2009-05-15       Impact factor: 4.939

4.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Authors:  Amelia Bartholomew; Cord Sturgeon; Mandy Siatskas; Karen Ferrer; Kevin McIntosh; Sheila Patil; Wayne Hardy; Steve Devine; David Ucker; Robert Deans; Annemarie Moseley; Ronald Hoffman
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

5.  A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells.

Authors:  C C Czerkinsky; L A Nilsson; H Nygren; O Ouchterlony; A Tarkowski
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

6.  T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression.

Authors:  Elena Klyushnenkova; Joseph D Mosca; Valentina Zernetkina; Manas K Majumdar; Kirstin J Beggs; Donald W Simonetti; Robert J Deans; Kevin R McIntosh
Journal:  J Biomed Sci       Date:  2005       Impact factor: 8.410

7.  Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells.

Authors:  Olga DelaRosa; Eleuterio Lombardo; Aitor Beraza; Pablo Mancheño-Corvo; Cristina Ramirez; Ramón Menta; Laura Rico; Eva Camarillo; Laura García; José Luis Abad; Cesar Trigueros; Mario Delgado; Dirk Büscher
Journal:  Tissue Eng Part A       Date:  2009-10       Impact factor: 3.845

Review 8.  Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions.

Authors:  Jeffery J Auletta; Kenneth R Cooke; Luis A Solchaga; Robert J Deans; Wouter van't Hof
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-16       Impact factor: 5.742

9.  Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use.

Authors:  H M Lazarus; S E Haynesworth; S L Gerson; N S Rosenthal; A I Caplan
Journal:  Bone Marrow Transplant       Date:  1995-10       Impact factor: 5.483

10.  Fibroblast Growth Factor-2 Enhances Expansion of Human Bone Marrow-Derived Mesenchymal Stromal Cells without Diminishing Their Immunosuppressive Potential.

Authors:  Jeffery J Auletta; Elizabeth A Zale; Jean F Welter; Luis A Solchaga
Journal:  Stem Cells Int       Date:  2011-03-03       Impact factor: 5.443

View more
  8 in total

1.  Microvescicles derived from mesenchymal stromal cells are not as effective as their cellular counterpart in the ability to modulate immune responses in vitro.

Authors:  Antonella Conforti; Marco Scarsella; Nadia Starc; Ezio Giorda; Simone Biagini; Alessandra Proia; Rita Carsetti; Franco Locatelli; Maria Ester Bernardo
Journal:  Stem Cells Dev       Date:  2014-07-31       Impact factor: 3.272

2.  Morphological features of IFN-γ-stimulated mesenchymal stromal cells predict overall immunosuppressive capacity.

Authors:  Matthew W Klinker; Ross A Marklein; Jessica L Lo Surdo; Cheng-Hong Wei; Steven R Bauer
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-10       Impact factor: 11.205

3.  Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation.

Authors:  Jeffery J Auletta; Saada K Eid; Patiwet Wuttisarnwattana; Ines Silva; Leland Metheny; Matthew D Keller; Rocio Guardia-Wolff; Chen Liu; Fangjing Wang; Theodore Bowen; Zhenghong Lee; Luis A Solchaga; Sudipto Ganguly; Megan Tyler; David L Wilson; Kenneth R Cooke
Journal:  Stem Cells       Date:  2015-02       Impact factor: 6.277

4.  Gastrointestinal microbes interact with canine adipose-derived mesenchymal stem cells in vitro and enhance immunomodulatory functions.

Authors:  Amir Kol; Soraya Foutouhi; Naomi J Walker; Nguyet T Kong; Bart C Weimer; Dori L Borjesson
Journal:  Stem Cells Dev       Date:  2014-06-26       Impact factor: 3.272

Review 5.  Establishing a bone marrow stromal cell transplant program at the National Institutes of Health Clinical Center.

Authors:  David F Stroncek; Marianna Sabatino; Jiaqiang Ren; Lee England; Sergei A Kuznetsov; Harvey G Klein; Pamela G Robey
Journal:  Tissue Eng Part B Rev       Date:  2014-02-07       Impact factor: 6.389

6.  Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism.

Authors:  Ayal Rozenberg; Ayman Rezk; Marie-Noëlle Boivin; Peter J Darlington; Mukanthu Nyirenda; Rui Li; Farzaneh Jalili; Raz Winer; Elinor A Artsy; Antonio Uccelli; Jane S Reese; Sarah M Planchon; Jeffrey A Cohen; Amit Bar-Or
Journal:  Stem Cells Transl Med       Date:  2016-07-11       Impact factor: 6.940

7.  The Phenotype and Functional Activity of Mesenchymal Stromal Cells in Pediatric Patients with Non-Malignant Hematological Diseases.

Authors:  Zyrafete Kuci; Christiane Jordan; Sibylle Wehner; Jan Sörensen; Andrea Jarisch; Emilia Salzmann-Manrique; Lisa-Marie Pfeffermann; Thomas Klingebiel; Peter Bader; Selim Kuҫi
Journal:  Cells       Date:  2020-02-12       Impact factor: 6.600

Review 8.  Mesenchymal stem cell-gut microbiota interaction in the repair of inflammatory bowel disease: an enhanced therapeutic effect.

Authors:  Dickson Kofi Wiredu Ocansey; Li Wang; Jingyan Wang; Yongmin Yan; Hui Qian; Xu Zhang; Wenrong Xu; Fei Mao
Journal:  Clin Transl Med       Date:  2019-12-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.